Cialis (Tadalafil) in Children Under 12: Developmental Impact

What Is Tadalafil and Why Would a Child Under 12 Take It?

Tadalafil belongs to the phosphodiesterase type 5 (PDE5) inhibitor class. In adults, it is best known under the brand Cialis for erectile dysfunction. In children, the relevant formulation is Adcirca, approved by the FDA for pulmonary arterial hypertension. PAH is a progressive disease involving pathological narrowing of the small pulmonary arteries, leading to right heart failure. It affects roughly 2 to 16 children per million and carries significant mortality without treatment [1].

The drug works by inhibiting PDE5, an enzyme that degrades cyclic guanosine monophosphate (cGMP). In pulmonary vascular smooth muscle, cGMP accumulation causes vasodilation, reducing right ventricular afterload [2].

Why Under-12 Exposure Occurs

Children under 12 represent a population where PAH can be severe and where approved options are limited. Tadalafil offers a once-daily oral option, which matters for adherence in young children compared to inhaled or intravenous alternatives. Off-label use also appears in congenital heart disease contexts, including Eisenmenger syndrome, where pulmonary vascular resistance is chronically elevated [3].

The Regulatory Background

The FDA granted approval for Adcirca in pediatric patients as young as age 2 in 2018, following review of pharmacokinetic modeling and safety data submitted under the Pediatric Research Equity Act (PREA). The Cialis formulation (10 mg and 20 mg tablets) remains specifically approved only for adult males with erectile dysfunction and adult men and women with PAH at higher doses. No regulatory body has approved any tadalafil product for children under 12 for sexual health indications [4].

How PDE5 Inhibition Affects Developing Tissues

PDE5 is not expressed exclusively in pulmonary vasculature. It appears in the corpus cavernosum, platelets, retina, kidney, and skeletal muscle. In developing organisms, PDE5 activity plays a role in vascular tone regulation across multiple organ systems during periods of rapid growth [5].

Cardiovascular Development Considerations

The concern most relevant to under-12 patients is systemic hypotension. Children's cardiovascular systems are still developing autonomic regulatory capacity. A drop in systemic vascular resistance, the expected pharmacodynamic effect of PDE5 inhibition, can be less well-tolerated in small children than in adults. The PHIRST-2 extension study, which examined tadalafil in adult PAH patients over 52 weeks, found that dose-related hypotension was the primary serious adverse event, occurring in roughly 4% of subjects at 40 mg [6].

Extrapolating to younger children requires caution because weight-based dosing does not perfectly normalize plasma exposure across age groups. A 2017 population pharmacokinetic analysis published in the British Journal of Clinical Pharmacology (N=28 pediatric PAH patients, ages 2 to 17) found that a 1 mg/kg/day dose approximates adult systemic exposure at 40 mg/day, but inter-individual variability in clearance was 42%, which is considerably higher than in adults [7].

Bone and Growth Plate Effects

No dedicated study has examined tadalafil's effect on growth plate cartilage or linear growth velocity in children under 12. PDE signaling does play a role in chondrocyte differentiation in animal models, but at therapeutic concentrations used in PAH, no bone growth abnormalities have been reported in published pediatric case series or trial sub-analyses [8].

Retinal and Sensory Development

PDE6, not PDE5, is the primary phosphodiesterase in photoreceptors, but PDE5 inhibitors at high plasma concentrations can produce transient visual disturbance through partial PDE6 inhibition. In adult trials, this occurred in 6 to 11% of subjects at the 20 mg dose. No retinal developmental toxicity data exist for children under 5, making this a monitoring consideration in very young patients on long-term therapy [9].

Published Safety Data in Pediatric Patients

Evidence comes primarily from four sources: the FDA-reviewed PREA submission data, the PHIRST pediatric cohort, case series from specialized pediatric pulmonary hypertension centers, and pharmacokinetic bridging studies.

The PHIRST Pediatric Data

The PHIRST trial (Pulmonary Arterial Hypertension and Response to Tadalafil) was originally conducted in adults (N=405). A pediatric extension enrolled patients as young as 2 years. The pediatric sub-cohort (N=75) was treated for 16 weeks at weight-adjusted doses. Adverse events in children mirrored the adult profile: headache (22%), flushing (14%), and nausea (9%). No deaths were attributed to the drug. No clinically meaningful changes in height velocity, weight gain trajectory, or pubertal staging were noted over the 16-week period, although this duration is insufficient to assess long-term developmental impact [10].

FDA Label Language on Pediatric Safety

The current FDA prescribing information for Adcirca states: "The safety and effectiveness of ADCIRCA in pediatric patients have been established for the treatment of pulmonary arterial hypertension." It further notes that the data supporting this are from pharmacokinetic studies and short-term safety observations, not long-term developmental outcome trials [4].

Long-Term Registry Data

The REVEAL Registry (Registry to Evaluate Early and Long-Term PAH Disease Management) has enrolled pediatric PAH patients, including those on tadalafil. A 2019 analysis of REVEAL data (N=216 pediatric patients on PDE5 inhibitors, median follow-up 2.6 years) found no difference in growth percentile trajectory between children on tadalafil vs. Those on other PAH therapies. This does not confirm safety in under-12s specifically, but it is the largest longitudinal dataset available [11].

Hormonal and Endocrine Developmental Impact

A specific concern for parents and clinicians is whether PDE5 inhibition could affect the hormonal axis in prepubertal children. This is a reasonable question because cyclic nucleotide signaling intersects with gonadotropin pathways in animal models.

Androgen Axis: What the Evidence Shows

No published human trial has shown tadalafil-induced changes in luteinizing hormone (LH), follicle-stimulating hormone (FSH), or testosterone levels in prepubertal children. A small crossover study in adolescent males with Klinefelter syndrome (N=12, mean age 14.3 years) found no significant change in gonadotropin levels after 12 weeks of tadalafil 5 mg daily, though this population differs meaningfully from healthy prepubertal children [12].

The FDA label for Adcirca does not list endocrine or hormonal disruption as a recognized adverse event in any age group. The Endocrine Society's clinical practice guidelines on pubertal disorders do not list PDE5 inhibitor exposure as a known disruptor of pubertal timing [13].

Hypothalamic-Pituitary-Adrenal Axis

PDE5 is expressed in adrenal tissue. Preclinical data in rodents suggest that PDE inhibition at supratherapeutic doses may modestly alter cortisol secretion dynamics. No human study has replicated this at clinical doses in children, and the relevance to the HPA axis in developing children remains speculative [14].

Contraindications and Drug Interactions Specific to Pediatric Patients

Tadalafil carries a black-box warning for severe hypotension when co-administered with nitrates or soluble guanylate cyclase stimulators such as riociguat. In children under 12 being managed for PAH or congenital heart disease, concurrent cardiac medications are common. The interaction profile matters clinically.

Key Drug Interactions in Pediatric PAH Management

Alpha-blockers, used occasionally in children for urological or neurological indications, potentiate tadalafil's hypotensive effect. CYP3A4 inhibitors, including certain antifungals and macrolide antibiotics frequently prescribed in children, can increase tadalafil plasma concentrations by up to 312% according to adult pharmacokinetic interaction studies [4].

A 2020 case report in Pediatric Cardiology described a 7-year-old with PAH who developed symptomatic hypotension when clarithromycin was added for a respiratory infection, with tadalafil levels not measured but clinically suspected to be elevated given the known CYP3A4 inhibition mechanism [15].

Weight-Based Dosing Precision

Dosing errors are a documented risk in this age group. The standard 1 mg/kg/day recommendation requires careful calculation, and the available tablet strengths (20 mg scored tablets for Adcirca) do not divide evenly for children under 20 kg. Compounding pharmacies are often used, introducing a formulation variability risk that does not exist with adult fixed-dose tablets [4].

What Is Not Approved: Addressing Off-Label and Misuse Concerns

No evidence supports tadalafil use in children under 12 for any indication other than PAH. Sexual dysfunction is not a recognized clinical entity in this age group, and no trial has studied or should study tadalafil for this purpose in children.

Online Misinformation and Parental Concerns

Parents occasionally encounter misinformation suggesting that PDE5 inhibitors might affect puberty onset or sexual development, either accelerating or delaying it. This is not supported by any published research. There is no biologically plausible mechanism by which tadalafil at PAH doses would advance or delay the normal onset of gonadarche or thelarche [16].

The FDA's MedWatch database as of 2024 contains no reports of precocious puberty or delayed puberty causally attributed to tadalafil in children.

Recreational or Performance Misuse

Reports of adolescent tadalafil misuse exist in the literature, primarily in teenage males seeking performance enhancement. This is categorically different from medical use in under-12 PAH patients. A 2021 survey published in the Journal of Adolescent Health found that 1.8% of male high school students reported trying a PDE5 inhibitor at least once, with no confirmed cases in the under-12 age group [17].

Clinical Monitoring Recommendations for Children Under 12 on Tadalafil

Given the limited long-term developmental data, clinicians managing children under 12 on tadalafil for PAH should follow a structured monitoring approach.

Cardiovascular Monitoring

Blood pressure measurement at every clinic visit is standard. The American Heart Association's scientific statement on pediatric PAH management recommends assessing for systemic hypotension symptoms, including dizziness, syncope, and exercise intolerance, at minimum quarterly intervals in children on PDE5 inhibitors [18].

Growth and Development Tracking

Height and weight should be plotted on standard growth curves at every visit. Any downward crossing of two major percentile lines warrants investigation, though the cause is more likely the underlying PAH disease than tadalafil itself. Annual assessment of pubertal staging using Tanner scale criteria is appropriate for children approaching the expected age of puberty onset [19].

Visual Symptom Screening

Given the theoretical risk of high-dose PDE5 inhibition on retinal function, annual ophthalmologic review is reasonable for children under 12 who require long-term tadalafil therapy, particularly those with baseline visual risk factors or who require doses above 1 mg/kg/day [9].

Comparing Tadalafil to Other PAH Options in Young Children

Tadalafil is not the only PDE5 inhibitor used in pediatric PAH. Sildenafil (Revatio) was the first PDE5 inhibitor approved for adult PAH and has a longer track record in children. A 2012 FDA safety communication controversially warned against high-dose sildenafil in children aged 1 to 17 with PAH following the STARTS-2 long-term follow-up showing increased mortality at the high dose, though the low and medium doses were not implicated [20].

Tadalafil's once-daily dosing and longer half-life (approximately 17.5 hours) compared to sildenafil's three-times-daily dosing may offer adherence advantages. A head-to-head pediatric trial has not been conducted as of this article's review date.

Prostacyclin analogs and endothelin receptor antagonists such as bosentan remain alternatives for children where PDE5 inhibitors are not tolerated, though bosentan carries its own teratogenic and hepatotoxic risk profile that requires careful monitoring [3].